Meeting
2019 ASCO Annual Meeting
Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (DPYD) genotype testing for fluoropyrimidine-based chemotherapy on adverse events and hospital costs.
Authors
Theodore John Wigle
University of Western Ontario, London, ON, Canada
Theodore John Wigle , Brandi Povitz , Wendy Teft , Robin Legan , John Gordon Lenehan , Markus Gulilat , Stephanie Nevison , Justin Kritzinger , Veera Punaganty , Denise Keller , Suhair AlShanteer , Robin Francis , Victoria Siebring , Sisira Sarma , Yun-Hee Choi , Stephen Welch , Eric Winquist , Ute Schwarz , Richard B. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3028)
DOI
10.1200/JCO.2019.37.15_suppl.3028
Abstract #
3028
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Quality Care Symposium
Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer.
First Author: Gabriel A. Brooks
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz
Poster
2018 ASCO Annual Meeting
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades.
First Author: Nauman S Siddiqui